Clostridium difficile infection (CDI) is diagnosed with the help of conventional laboratory testing methods, however, rapid point-of-care diagnostic tests are also available, which can save time and costs significantly. Diagnostic assays used for detection of CDI include enzyme immunoassays (EIAs) for toxins A/B. However, these are no longer considered stand-alone primary tests due to poor sensitivity. Other tests include glutamate dehydrogenase enzyme immunoassay and molecular assay based on polymerase chain reaction. Isothermal amplification technology has also been approved by the U.S. Food & Drug Administration for diagnosis of CDI. Manufacturers such as Cepheid, BD Diagnostics, DiaSorin, Inc., Abbott Laboratories, Thermo Fisher Diagnostics, and Luminex Corporation offer advanced diagnostic tests for clostridium difficile infection. For instance, Cepheid GeneXpert test, Nanosphere Verigene SP by Luminex Corporation offer sensitivity and timely results for clostridium difficile infection.
Market Dynamics
Factors such as rising prevalence of clostridium difficile infection, availability of precise and advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and presence of generic versions of standard antibiotics such as metronidazole is expected to boost growth of the clostridium difficile diagnostics and treatment market over the forecast period. Furthermore, various organizations and manufacturers are working towards increasing awareness about clostridium difficile infection and its severity. For instance, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc.—a pharmaceutical company, for contribution of the company towards increasing awareness and expanding treatment options.
Key features of the study:
- This report provides in-depth analysis of clostridium difficile diagnostics and treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global clostridium difficile diagnostics and treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key companies covered as a part of this study include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global clostridium difficile diagnostics and treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the clostridium difficile diagnostics and treatment market
Detailed Segmentation:
- Global Clostridium Difficile Diagnostics and Treatment Market, By Product Type:
- By Drug
- Metronidazole
- Vancomycin
- Fidaxomicin
- Bezlotoxumab
- By Diagnostic Test
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
- Others
- Global Clostridium Difficile Diagnostics and Treatment Market, By Distribution Channel:
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmacies
- Global Clostridium Difficile Diagnostics and Treatment Market, By Geography:
- North America
- By Product Type:
- By Drug
- Metronidazole
- Vancomycin
- Fidaxomicin
- Bezlotoxumab
- By Diagnostic Test
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
- Others
- By Distribution Channel:
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmacies
- By Country:
- Europe
- By Product Type:
- By Drug
- Metronidazole
- Vancomycin
- Fidaxomicin
- Bezlotoxumab
- By Diagnostic Test
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
- Others
- By Distribution Channel:
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- By Drug
- Metronidazole
- Vancomycin
- Fidaxomicin
- Bezlotoxumab
- By Diagnostic Test
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
- Others
- By Distribution Channel:
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmacies
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Product Type:
- By Drug
- Metronidazole
- Vancomycin
- Fidaxomicin
- Bezlotoxumab
- By Diagnostic Test
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
- Others
- By Distribution Channel:
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmacies
- By Country:
- Brazil
- Mexico
- Rest of Latin America
- Middle East
- By Product Type:
- By Drug
- Metronidazole
- Vancomycin
- Fidaxomicin
- Bezlotoxumab
- By Diagnostic Test
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
- Others
- By Distribution Channel:
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- By Drug
- Metronidazole
- Vancomycin
- Fidaxomicin
- Bezlotoxumab
- By Diagnostic Test
- Enzyme Immunoassays
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Nucleic Amplification Tests (NAAT)
- Others
- By Distribution Channel:
- Hospitals & Clinics
- Diagnostic Laboratories
- Pharmacies
- By Country:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Roche AG *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Thermo Fisher Scientific
- Merck & Co., Inc.
- Pfizer, Inc.
- Actelion Pharmaceuticals, Inc.
- Abbott Laboratories
- Trinity Biotech
- Summit Therapeutics
- Sanofi S.A.
- Novartis AG
- AstraZeneca Plc
“*” marked represents similar segmentation in other categories in the respective section.
